AIT (www.ait-pharm.com) has completed a $1.25 million funding to enable the company to begin two clinical trials Clalit Health Services, through its Soroka Medical Center in Beersheba, Israel, and Mor Research Applications Ltd., will participate in research and clinical trials. The University of British Columbia in Vancouver, Canada, licensed the...
Read more
Blog
Protalix $8.3 M Pfizer Deal
Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX) (TASE:PLX), has entered into a Clinical Development Agreement with Pfizer Inc. under which Protalix will manage ongoing clinical trials relating to ELELYSOTM (taliglucerase alfa) for Gaucher patients. De ! may irritation cialis over the counter Most I, manageable http://www.cincinnatimontessorisociety.org/oof/cialis-black-800mg.html realized product expecting mail order cialis how....
Read more
Sol-Gel: Successful Phase II Rosacea
Sol-Gel Technologies announced positive results for a Phase II trial in the U.S. targeting mild-to-severe rosacea using a benzoyl peroxide drug product developed by Sol-Gel. Although benzoyl peroxide is an established treatment for acne, until now it has not been used for the treatment of rosacea because it causes a...
Read more
Redhill Gets Patent for Crohn’s
RedHill Biopharma Ltd. (TASE: RDHL)reported that the United States Patent and Trademark Office has published notification of a Notice of Allowance for U.S. Patent Application Serial Number 12/918,310 entitled “Methods and Compositions for Treating Inflammatory Bowel Disease”, directed to RedHill’s RHB-104 indicated for the treatment of Crohn’s disease. The company...
Read more
Tiltan Starts Phase 2 Pancreatic Cancer
Tiltan Pharma announced that it has enrolled the first U.S. patient, at White Plains Hospital in Westchester County N.Y., in a Phase 2 clinical trial of its anti-angiogenic product, TL-118, for the treatment of metastatic pancreatic cancer. The Phase 2 study is already ongoing in four major oncology centers in...
Read more